IL314600A - Combination therapy for use in treatment of non-small cell lung cancer - Google Patents

Combination therapy for use in treatment of non-small cell lung cancer

Info

Publication number
IL314600A
IL314600A IL314600A IL31460024A IL314600A IL 314600 A IL314600 A IL 314600A IL 314600 A IL314600 A IL 314600A IL 31460024 A IL31460024 A IL 31460024A IL 314600 A IL314600 A IL 314600A
Authority
IL
Israel
Prior art keywords
treatment
lung cancer
small cell
cell lung
combined therapy
Prior art date
Application number
IL314600A
Other languages
English (en)
Hebrew (he)
Original Assignee
Alethia Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics Inc filed Critical Alethia Biotherapeutics Inc
Publication of IL314600A publication Critical patent/IL314600A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL314600A 2022-02-07 2023-02-06 Combination therapy for use in treatment of non-small cell lung cancer IL314600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263307533P 2022-02-07 2022-02-07
US202263333597P 2022-04-22 2022-04-22
PCT/CA2023/050151 WO2023147673A1 (en) 2022-02-07 2023-02-06 Combination therapy for use in treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
IL314600A true IL314600A (en) 2024-09-01

Family

ID=87553087

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314600A IL314600A (en) 2022-02-07 2023-02-06 Combination therapy for use in treatment of non-small cell lung cancer

Country Status (9)

Country Link
US (1) US20250108110A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475885A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505652A (cg-RX-API-DMAC7.html)
KR (1) KR20240153627A (cg-RX-API-DMAC7.html)
AU (1) AU2023216333A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243096A1 (cg-RX-API-DMAC7.html)
IL (1) IL314600A (cg-RX-API-DMAC7.html)
MX (1) MX2024009671A (cg-RX-API-DMAC7.html)
WO (1) WO2023147673A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2928846A1 (en) * 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
CA2862739A1 (en) * 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
EP4329801A4 (en) * 2021-04-27 2025-05-14 Alethia Biotherapeutics Inc. Method for allowing immune cells infiltration in tumors

Also Published As

Publication number Publication date
WO2023147673A1 (en) 2023-08-10
AU2023216333A1 (en) 2024-08-22
CA3243096A1 (en) 2023-08-10
MX2024009671A (es) 2024-08-19
EP4475885A4 (en) 2026-02-18
JP2025505652A (ja) 2025-02-28
KR20240153627A (ko) 2024-10-23
EP4475885A1 (en) 2024-12-18
US20250108110A1 (en) 2025-04-03

Similar Documents

Publication Publication Date Title
MX2025002382A (es) Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer
SI3849534T1 (sl) Kombinacija dasatiniba in adagrasiba za uporabo pri zdravljenju nedrobnoceličnega pljučnega raka
IL276406A (en) Osimertinib for use in the treatment of non-small cell lung cancer
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
WO2011112953A3 (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP4442710A4 (en) Combination of drugs for the treatment of non-small cell lung cancer
EA201691385A1 (ru) Комбинированная терапия рака
LT4340842T (lt) Sotorasibas, skirtas naudoti vėžio gydymui
EP4440623A4 (en) Polytherapy for the treatment of cancer
HUE070568T2 (hu) Heterociklusos vegyületek rák kezelésében való alkalmazásra
BR112014012495A2 (pt) método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer
GB202317288D0 (en) Pyrrolopyridone derivatives useful in the treatment of cancer
JOP20200124A1 (ar) طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
IL308992A (en) Cancer treatment in patients with soluble FR-alpha
BR112018011196A2 (pt) uso de pirimido-pirimidazinonas para tratar o câncer
DK1971338T3 (da) Kombination af ZD6474 og pemetrexed
IL315441A (en) Treatment methods for small cell lung cancer
IL312249A (en) Combination therapy for treating lung cancer
EA201391438A1 (ru) Производные сулиндака, применение и получение указанных производных
EP3817740A4 (en) COMBINATION THERAPY WITH TARGETED TGF-B INHIBITION FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
EP4281063A4 (en) OXABICYCLOHEPTANE FOR THE TREATMENT OF SMALL CELL LUNG CANCER
IL326946A (en) Methods of treating non-small cell lung cancer
DK1965801T3 (da) Kombination af azd2171 og pemetrexed
HK40116955A (en) Combination therapy for use in treatment of non-small cell lung cancer
CA3243096A1 (en) POLYTHERAPY INTENDED FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER